Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFYX-004
- Development stage
- Unknown
- Lead developer
- AFYX Therapeutics
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
AFYX-004 is a small molecule nasal spray formulation being developed by AFYX Therapeutics for the treatment of cluster headache. It acts by modulating the N-methyl-D-aspartate (NMDA) receptor. The drug is currently in Phase 2 clinical development, aiming to provide acute relief for cluster headache patients through a non-invasive intranasal route of administration. By targeting the NMDA receptor, AFYX-004 seeks to address the underlying pathophysiology of cluster headache attacks, which are characterized by severe, debilitating pain.
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR2A (Serotonin receptor 5-HT2A)NMDAR (Glutamate receptor ionotropic, NMDA)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on AFYX-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFYX-004.